SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Icebrg who wrote (1757)8/7/2003 7:03:31 PM
From: Icebrg  Read Replies (2) of 3044
 
The Medicines Company Report - Angiomax

Judging from MDCO's recent Q2-report Angiomax has not really started to move yet. Revenue development over the last 6 quarters.


          Q2_03	 Q1_03  Q4_02  Q3_02  Q2_02  Q1_02
							
Revenue	  18,8   16,7   14,3    9,1    7,2    7,7



MDCO will not specify its revenue any further. Some of the revenue might actually come from other sources. But in their 10K they wrote that most of it comes from Angiomax. Looking at these figures it does not look as if the slow-down in Integrelin sales is due to increasing competition from Angiomax.

Erik
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News